Newsfile Corp
03 Aug 2026, 21:43 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail's NHS-Galleri trial failed to observe the primary endpoint of a statistically significant reduction in Stage III and IV cancers. — The failure of a primary clinical endpoint for a core product typically triggers severe valuation resets and undermines the company's growth thesis.
-0.90A federal securities class action lawsuit has been filed against Grail alleging that the company concealed material adverse facts regarding the NHS-Galleri trial. — Legal action alleging securities fraud introduces significant litigation risk and potential financial liabilities beyond the trial failure itself.
-0.40Grail's common stock price fell approximately 50.55% in a single day following the announcement of the trial results on February 19, 2026. — This confirms a massive loss of market capitalization and high investor volatility, though the move has already occurred.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a federal securities class action lawsuit following a 50% stock price drop and failure to meet a primary trial endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
